US2022098229A1PendingUtilityA1

Crystal forms of beta-nicotinamide mononucleotide

Individually held — no corporate assignee on recordPriority: Oct 2, 2015Filed: Jun 9, 2021Published: Mar 31, 2022
Est. expiryOct 2, 2035(~9.2 yrs left)· nominal 20-yr term from priority
C07H 19/048C07H 1/00C07B 2200/13A61P 43/00A61K 31/706A61K 31/7052
75
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to crystalline forms of a β-nicotinamide mononucleotide, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for nutraceutical, veterinary, and agriculturally-relevant uses.

Claims

exact text as granted — not AI-modified
1 - 28 . (canceled) 
     
     
         29 . A solid composition comprising a compound having the structure of formula (I), 
       
         
           
           
               
               
           
         
       
       or a salt thereof, and further comprising one or more solid orally-acceptable excipients or carriers, wherein said composition is in a unit dosage form for human administration of 0.01 to 3000 mg, and further wherein said composition is formulated as a dietary supplement. 
     
     
         30 . The solid composition of  claim 29 , wherein said composition is pyrogen-free. 
     
     
         31 . The solid composition of  claim 29 , wherein said composition is non-pyrogenic. 
     
     
         32 . The solid composition of  claim 29 , wherein said unit dosage form is a pill. 
     
     
         33 . The solid composition of  claim 29 , wherein said unit dosage form is a tablet. 
     
     
         34 . The solid composition of  claim 29 , wherein said unit dosage form is a capsule. 
     
     
         35 . The solid composition of  claim 34 , wherein said capsule is a gelatin capsule. 
     
     
         36 . The solid composition of  claim 29 , wherein said one or more solid orally-acceptable excipients or carriers comprise gelatin. 
     
     
         37 . The solid composition of  claim 29 , wherein said one or more solid orally-acceptable excipients or carriers comprise hydroxypropylmethyl cellulose. 
     
     
         38 . The solid composition of  claim 29 , wherein said one or more solid orally-acceptable excipients or carriers comprise sodium carboxymethyl cellulose. 
     
     
         39 . A method of preparing a dietary supplement comprising combining (i) a compound having the structure of formula (I), 
       
         
           
           
               
               
           
         
       
       or a salt thereof, with (ii) one or more solid orally-acceptable excipients or carriers, to form a solid composition, 
       wherein said composition is in a unit dosage form for human administration of 0.01 to 3000 mg, and further wherein said composition is formulated as a dietary supplement. 
     
     
         40 . The method of  claim 39 , wherein said composition is pyrogen-free. 
     
     
         41 . The method of  claim 39 , wherein said composition is non-pyrogenic. 
     
     
         42 . The method of  claim 39 , wherein said unit dosage form is a pill. 
     
     
         43 . The method of  claim 39 , wherein said unit dosage form is a tablet. 
     
     
         44 . The method of  claim 39 , wherein said unit dosage form is a capsule. 
     
     
         45 . The method of  claim 39 , wherein said one or more solid orally-acceptable excipients or carriers comprise gelatin. 
     
     
         46 . The method of  claim 39 , wherein said one or more solid orally-acceptable excipients or carriers comprise hydroxypropylmethyl cellulose. 
     
     
         47 . The method of  claim 39 , wherein said one or more solid orally-acceptable excipients or carriers comprise sodium carboxymethyl cellulose. 
     
     
         48 . A method of supplementing a diet comprising providing a composition to a human for self-administration, wherein the composition is a solid composition comprising a compound having the structure of formula (I), 
       
         
           
           
               
               
           
         
       
       or a salt thereof, and further comprising one or more solid orally-acceptable excipients or carriers, wherein said composition is in a unit dosage form for human administration of 0.01 to 3000 mg, and further wherein said composition is formulated as a dietary supplement.

Join the waitlist — get patent alerts

Track US2022098229A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.